Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference
Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference
Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK is the Company's first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit , and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).PITTSBURGH, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Guggenheim Securities Healthcare Innovation Conference on November 12, 2024, in Boston. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 1:30 pm ET and host investor meetings throughout the day.
匹兹堡，2024年11月06日（环球新闻社） -- krystal biotech股份有限公司（"公司"）（纳斯达克：KRYS），一家商业阶段的生物技术公司，今天宣布公司将参加于2024年11月12日在波士顿举行的古根海姆证券医疗创新大会。首席执行官兼主席Krish S. Krishnan将参加于下午1:30 Et举行的炉边聊天，并全天举行投资者会议。
A webcast of the presentation will be available here beginning at 1:30 pm ET on Tuesday, November 12, 2024 and will be posted on the Investors section of the Company's website.
演示文稿的网络直播将于2024年9月10日ET下午12:30开始，将在该公司的投资者部分发布。 here 从2024年11月12日星期二下午1:30 Et开始，将在公司的投资者部分发布。 网站.
About Krystal Biotech, Inc.
关于krystal biotech，公司
Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK is the Company's first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit , and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
Krystal Biotech公司（纳斯达克：KRYS）是一家专注于发现、开发和商业化用于治疗高度未满足医疗需求疾病的基因药物的商业阶段生物技术公司。VYJUVEk是公司的首个商业产品，也是首个可以重复使用的基因治疗产品，也是美国食品药品监督管理局批准用于治疗肌萎缩性表皮溢脓性松解症的第一药物。该公司正在快速推进一个强大的临床前和临床试验管线，研发调查用于呼吸系统、肿瘤学、皮肤科、眼科医疗和美容领域的基因药物。Krystal Biotech总部位于宾夕法尼亚州匹兹堡。欲了解更多信息，请访问 ，并在（原twitter）上关注@KrystalBiotech领英 和 X，并在（原twitter）上关注@KrystalBiotech
CONTACT
Investors and Media:
Stéphane Paquette
Krystal Biotech
spaquette@krystalbio.com
联系方式
投资者和媒体：
Stéphane Paquette
krystal biotech
spaquette@krystalbio.com
